New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
07:41 EDTALDXAldeyra reports Q2 EPS ($1.56), may not compare to one estimate (53c)
Net loss per share for the respective period includes the effect of the change in fair value of derivative instruments carried as liabilities on the balance sheet that are marked to market at the end of each reporting period. As of June 30, there were no derivative liabilities outstanding as a result of the net exercise of those instruments.
News For ALDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
08:33 EDTALDXAldeyra submits FDA IND filing for noninfectious anterior uveitis
Aldeyra Therapeutics submitted an Investigational New Drug application to conduct Phase 2 clinical testing of NS2 for the treatment of noninfectious anterior uveitis to the FDA on December 16. Noninfectious anterior uveitis is a rare disease that affects an estimated 25,000 patients per year in the U.S. Aldeyra has developed an ophthalmic formulation of its lead product candidate, NS2, to treat this disease and intends to initiate a Phase 2 trial for this indication in 2015, pending FDA review of the IND.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use